GSK has been the topic of a number of other reports. UBS Group upgraded GlaxoSmithKline from a neutral rating to a buy rating and lifted their price target for the company from $35.04 to $35.85 in a research note on Monday, November 27th. Zacks Investment Research cut GlaxoSmithKline from a buy rating to a hold rating in a report on Thursday, January 4th. ValuEngine cut GlaxoSmithKline from a buy rating to a hold rating in a report on Sunday, December 31st. JPMorgan Chase & Co. reaffirmed a neutral rating on shares of GlaxoSmithKline in a report on Thursday, January 11th. Finally, Barclays raised GlaxoSmithKline from an equal weight rating to an overweight rating in a report on Tuesday, January 16th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and six have given a buy rating to the company. The stock presently has a consensus rating of Hold and an average price target of $38.97.
Shares of GlaxoSmithKline (NYSE GSK) opened at $37.70 on Thursday. The company has a quick ratio of 0.39, a current ratio of 0.60 and a debt-to-equity ratio of 4.09. GlaxoSmithKline has a 12 month low of $34.52 and a 12 month high of $44.53. The firm has a market capitalization of $91,790.00, a P/E ratio of 43.33, a P/E/G ratio of 2.37 and a beta of 0.98.
GlaxoSmithKline (NYSE:GSK) last posted its quarterly earnings results on Wednesday, February 7th. The pharmaceutical company reported $0.72 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.69 by $0.03. GlaxoSmithKline had a return on equity of 130.63% and a net margin of 4.97%. The firm had revenue of $10.14 billion for the quarter, compared to the consensus estimate of $9.89 billion. research analysts anticipate that GlaxoSmithKline will post 2.85 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, April 12th. Investors of record on Friday, February 23rd will be issued a dividend of $0.633 per share. The ex-dividend date of this dividend is Thursday, February 22nd. This is a boost from GlaxoSmithKline’s previous quarterly dividend of $0.50. This represents a $2.53 annualized dividend and a yield of 6.72%. GlaxoSmithKline’s payout ratio is currently 234.48%.
A number of hedge funds have recently modified their holdings of GSK. Wealthcare Advisory Partners LLC raised its holdings in shares of GlaxoSmithKline by 1,982.8% in the third quarter. Wealthcare Advisory Partners LLC now owns 3,520 shares of the pharmaceutical company’s stock worth $143,000 after acquiring an additional 3,351 shares during the last quarter. Field & Main Bank acquired a new position in shares of GlaxoSmithKline in the fourth quarter worth $132,000. Amussen Hunsaker Associates LLC acquired a new position in shares of GlaxoSmithKline in the fourth quarter worth $141,000. First Dallas Securities Inc. acquired a new position in shares of GlaxoSmithKline in the fourth quarter worth $142,000. Finally, Advisory Services Network LLC raised its holdings in shares of GlaxoSmithKline by 24.2% in the second quarter. Advisory Services Network LLC now owns 4,047 shares of the pharmaceutical company’s stock worth $175,000 after acquiring an additional 788 shares during the last quarter. 9.52% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: This piece was originally published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this piece on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this piece can be viewed at https://ledgergazette.com/2018/02/18/glaxosmithkline-gsk-given-hold-rating-at-cowen.html.
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.